{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005670162,0.0002982718,0.0008739301,0.000171404,0.0001138284,0.00001384955,0.0001109999,0.0000906733,0.0002242875],"category_scores_gemma":[0.0005532072,0.000160751,0.0001318814,0.0004303414,0.001515938,0.0003092261,0.00004294228,0.0002038021,0.000003375177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002033919,"about_ca_system_score_gemma":0.001072135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007425509,"about_ca_topic_score_gemma":0.00004261001,"domain_scores_codex":[0.9974299,0.0003329073,0.0008252612,0.0004036166,0.0007252316,0.000283079],"domain_scores_gemma":[0.9976749,0.000911526,0.0005734825,0.0002503595,0.0002989171,0.0002908262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9625975,0.000584293,0.002086466,0.0000216459,0.0002010149,0.000001766661,0.001449912,0.000004130965,0.0009028901,0.001410367,0.001304065,0.02943587],"study_design_scores_gemma":[0.9782951,0.0007816804,0.004987423,0.0009471746,0.0001324503,0.000004650724,0.00004252095,0.00003416926,0.009729253,0.004441997,0.0003809945,0.000222566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9726589,0.0007396127,0.00007301426,0.02247703,0.0005316421,0.002821297,0.0005315164,0.00003124995,0.0001356768],"genre_scores_gemma":[0.9956955,0.0001990567,0.0008699909,0.001474697,0.0005489763,0.0005129125,0.00007552395,0.00003610938,0.0005872837],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02921331,"threshold_uncertainty_score":0.6555238,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01259685493353731,"score_gpt":0.2914200369288869,"score_spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}